Prostate cancer stem cells: Are they androgen-responsive?
| Autor: | Emma E. Oldridge, Norman J. Maitland, Anne T. Collins, Davide Pellacani |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Neoplasms Hormone-Dependent medicine.drug_class Biology urologic and male genital diseases Biochemistry TMPRSS2 Epithelium Prostate cancer Endocrinology Prostate Cancer stem cell Internal medicine LNCaP medicine Animals Humans Molecular Targeted Therapy Molecular Biology Prostatic Neoplasms Androgen medicine.disease Gene Expression Regulation Neoplastic Androgen receptor Cell Transformation Neoplastic medicine.anatomical_structure Androgens Neoplastic Stem Cells Cancer research Stem cell |
| Zdroj: | Molecular and Cellular Endocrinology. 360:14-24 |
| ISSN: | 0303-7207 |
| DOI: | 10.1016/j.mce.2011.07.008 |
| Popis: | The prostate gland is highly dependent on androgens for its development, growth and function. Consequently, the prostatic epithelium predominantly consists of androgen-dependent luminal cells, which express the androgen receptor at high levels. In contrast, androgens are not required for the survival of the androgen-responsive, but androgen-independent, basal compartment in which stem cells reside. Basal and luminal cells are linked in a hierarchical pathway, which most probably exists as a continuum with different stages of phenotypic change. Prostate cancer is also characterised by heterogeneity, which is reflected in its response to treatment. The putative androgen receptor negative cancer stem cell (CSC) is likely to form a resistant core after most androgen-based therapies, contributing to the evolution of castration-resistant disease. The development of CSC-targeted therapies is now of crucial importance and identifying the phenotypic differences between CSCs and both their progeny will be key in this process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect